Monday, October 3, 2022


Biotechnology News Magazine

Vivan Therapeutics Partners with Perlara to Identify Novel Therapeutics for Rare Genetic Diseases

Latest Posts

City of Hope to Accelerate Immunotherapy Research & Treatment Innovation with $15 Mil Gift from Ted Schwartz Family

Ted Schwartz, who is now cancer free, achieved complete remission at City of Hope in 2020 with the center's leading CAR T cell therapy after a 16-year battle with lymphoma, provided the gift to City of Hope to advance treatment options that offer better outcomes and quality of life for people living with cancer.

Neurocrine Biosciences Appoints Dr Ingrid Delaet as Chief Regulatory Officer

Prior to joining Neurocrine Biosciences, Dr Ingrid Delaet served as Senior Vice President, Regulatory Affairs at Intercept Pharmaceuticals, which she joined in 2016.

Astrea Bioseparations Introduces Nereus LentiHERO, a Fit-for-purpose Solution for Lentiviral Vector Purification

“We believe that AstreAdept will be a game-changer,” explained Astrea Bioseparations’ CEO Terry Pizzie. “Our approach was to rapidly develop and incorporate this material into the Nereus LentiHERO, a simple, fit-for-purpose device that radically transforms how lentivirus can be purified [in terms of speed, recovery, and efficiency].

At Pack Expo, Schreiner MediPharm to Debut Functional Labels Designed from More Sustainable Materials

Schreiner MediPharm advises he new label concepts are based on existing items in Schreiner MediPharm’s roster of functional labeling solutions.

Vivan Therapeutics notes Perlara PBC, a rare disease public benefit company today announced a rare genetic diseases collaboration with Vivan Therapeutics to identify novel therapeutics for rare genetic diseases.

Under this agreement, Perlara will refer highly motivated patients, families and foundations seeking to embark on a discovery journey for a rare genetic disease to Vivan Therapeutics. Vivan’s technology known as the Personal Discovery Process (PDP), enables the design and generation of personalised fruit fly (Drosophila melanogaster) ‘avatars’. Using robotics, thousands of FDA approved drugs and other drug libraries are screened in combinations to identify potential therapeutics.

Chief Scientific Officer Dr Nahuel Villegas comments, “Our fruit fly in vivo models are specifically designed to identify novel and unlikely therapies for diseases with clear genetic components. In this exciting collaboration with Perlara we will employ our unique platform to run massive drug screenings to define therapeutic options for diseases with no current standard of care treatments.”

The first two diseases to be modelled are MAN1B1-CDG (congenital disorder of glycosylation) and ECHS1 deficiency. The ECHS1 gene and MAN1B1 gene are very well conserved in fruit flies.

Individuals with MAN1B1-CDG have two deficient copies of the MAN1B1 gene. Currently, there are no treatments for this disease. Individuals with MAN1B1-CDG typically develop signs and symptoms of the condition during infancy, including a broad array of phenotypic abnormalities such as developmental disability, decreased muscle tone (hypotonia), delayed motor skills, and behavioural problems among others.

ECHS1 deficiency is a rare congenital metabolic disorder caused by biallelic mutations in the ECHS1 gene. Individuals with this mitochondrial condition typically have signs and symptoms of developmental delay, dystonia, seizures, and brain abnormalities.

Ethan Perlstein, CEO of Perlara commented, “We’re excited to be working with Vivan on developing fly avatars of monogenic inborn errors of metabolism for rapid turnaround personalized drug repurposing. Flies are at the sweet spot of disease model complexity and clinical translatability.”

Laura Towart, CEO of Vivan Therapeutics added, “This collaboration is our first outside of oncology and will enable us to utilise our platform technology to potentially identify therapeutics for diseases for which there are no treatments. We are looking forward to embarking on this important mission with Perlara and the families.”

Latest Posts

Learn More




Our Sister Publication

Medical Device News Magazine